Kiniksa Pharmaceuticals International, plc
KNSA
$56.51
-$2.03-3.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 56.71% | 60.09% | 55.68% | 56.18% | 59.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.71% | 60.09% | 55.68% | 56.18% | 59.45% |
| Cost of Revenue | 55.78% | 62.36% | 88.65% | 95.97% | 107.09% |
| Gross Profit | 57.49% | 58.26% | 34.64% | 32.44% | 33.65% |
| SG&A Expenses | 23.74% | 16.82% | 9.63% | 16.44% | 24.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.97% | 28.04% | 36.43% | 43.23% | 49.55% |
| Operating Income | 689.90% | 269.28% | 245.43% | 116.27% | 48.26% |
| Income Before Tax | 1,779.35% | 345.82% | 390.74% | 179.14% | 70.73% |
| Income Tax Expenses | 209.48% | 324.13% | 265.93% | 221.58% | 135.21% |
| Earnings from Continuing Operations | 531.02% | 236.61% | 496.10% | 146.82% | -295.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 531.02% | 236.61% | 496.10% | 146.82% | -295.95% |
| EBIT | 689.90% | 269.28% | 245.43% | 116.27% | 48.26% |
| EBITDA | 766.95% | 279.36% | 262.46% | 123.47% | 49.78% |
| EPS Basic | 509.31% | 231.11% | 490.40% | 141.83% | -290.38% |
| Normalized Basic EPS | 1,694.57% | 336.91% | 378.49% | 174.55% | 71.14% |
| EPS Diluted | 460.18% | 222.40% | 421.42% | 123.71% | -322.82% |
| Normalized Diluted EPS | 1,440.46% | 322.45% | 355.15% | 163.39% | 68.02% |
| Average Basic Shares Outstanding | 4.50% | 3.88% | 3.31% | 2.81% | 2.34% |
| Average Diluted Shares Outstanding | 10.56% | 10.50% | 7.14% | 4.80% | 2.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |